Show
Sort by
-
Modeling the relationship between exposure to abiraterone and prostate-specific antigen dynamics in patients with metastatic castration-resistant prostate cancer
-
Population pharmacokinetic modeling of tapentadol extended release (ER) in healthy subjects and patients with moderate or severe chronic pain
-
Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia
-
Correlation between prostate-specific antigen kinetics and overall survival in abiraterone acetate-treated castration-resistant prostate cancer patients
-
Population pharmacokinetic analysis of abiraterone in chemotherapy-Na < ve and docetaxel-treated patients with metastatic castration-resistant prostate cancer
-
Mixed-effects beta regression for modeling continuous bounded outcome scores using NONMEM when data are not on the boundaries
-
Modeling continuous bounded outcome scores using beta regression with NONMEM (R) VII
-
Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact
-
Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models